ResearchMoz

Immunovaccine, Inc. Product Pipeline Review 2012

Publisher Name » Global Markets Direct
Published Date » 2012-10-31
No. Of Pages » 84

Immunovaccine, Inc. Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, ImmunoVaccine Technologies Inc. Product Pipeline Review 2012 provides data on the ImmunoVaccine Technologies Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, ImmunoVaccine Technologies Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoVaccine Technologies Inc. and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • ImmunoVaccine Technologies Inc. Brief ImmunoVaccine Technologies Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of ImmunoVaccine Technologies Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of ImmunoVaccine Technologies Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the ImmunoVaccine Technologies Inc.s pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate ImmunoVaccine Technologies Inc.s strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of ImmunoVaccine Technologies Inc. in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the ImmunoVaccine Technologies Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with ImmunoVaccine Technologies Inc.. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of ImmunoVaccine Technologies Inc. and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Immunovaccine, Inc. Snapshot 7
Immunovaccine, Inc. Overview 7
Key Information 7
Key Facts 7
Immunovaccine, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Immunovaccine, Inc. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products –  Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Immunovaccine, Inc. – Pipeline Products Glance 14
Immunovaccine, Inc. Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Immunovaccine, Inc. – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Immunovaccine, Inc. – Drug Profiles 17
Anthrax Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cocaine Addiction Vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
DPX-0907 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
DPX-Survivac 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
DPX-Survivac + Low Dose Cyclophosphamide 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Hepatitis B Vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HPV Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IRX-2 + DepoVax 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Malaria Vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Pandemic Influenza Vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Respiratory Syncytial Virus Vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Vaccine For Multifiloviruses 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Immunovaccine, Inc. – Pipeline Analysis 32
Immunovaccine, Inc. – Pipeline Products by Therapeutic Class 32
Immunovaccine, Inc. – Pipeline Products by Route of Administration 33
Immunovaccine, Inc. – Pipeline Products By Mechanism of Action 34
Immunovaccine, Inc. –  Recent Pipeline Updates 35
Immunovaccine, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
DPX-Pseudomonas 38
Immunovaccine, Inc. – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Immunovaccine, Inc., Recent Developments 40
Immunovaccine, Inc.- Press Release 40
Oct 09, 2012: Immunovaccine Reports Positive Interim Results From Phase I Study Of Ovarian Cancer Vaccine Candidate DPX-Survivac 40
Aug 06, 2012: Immunovaccine Announces Publication Of Positive Clinical Trial Results For DPX-0907 In Journal Of Translational Medicine 41
Jun 20, 2012: Immunovaccine Announces Presentation Of DPX-Survivac Data At Federation of Clinical Immunology Societies Conference 43
Jun 04, 2012: Immunovaccine Presents Positive Phase I Results Of DPX-0907 In Multiple Cancers At ASCO Annual Meeting 2012 44
May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting 45
Apr 03, 2012: Immunovaccine Presents Findings Of Cancer Vaccine Studies At AACR Meeting 45
Jan 04, 2012: Immunovaccine Initiates Phase I Trial Of DPX-Survivac Cancer Vaccine 46
Dec 10, 2009: Immunovaccine Inc. Announces Approval Of Investigational Drug Application For Its Therapeutic Cancer Vaccine, DPX-0907 47
Dec 09, 2009: Immunovaccine Receives Clearance From FDA For Phase 1 Clinical Trial For Its Therapeutic Cancer Vaccine, DPX-0907 47
Jul 14, 2009: ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens 48
Financial Deals Landscape 49
Immunovaccine, Inc., Deals Summary 49
Immunovaccine, Inc., Pharmaceuticals & Healthcare, Deal Details 51
Partnerships 51
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 51
ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 52
Immunovaccine Technologies Enters Into Research Agreement With OncoTherapy Science 53
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 54
Immunovaccine Enters Into Co-Development Agreement With Oncothyreon 55
Immunovaccine Enters Into Research Agreement With Vaxil BioTherapeutics 56
ImmunoVaccine Enters Into Research Agreement With Dana-Farber 57
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute 62
Immunovaccine Expands Research Agreement With Defence Research And Development Canada 63
ImmunoVaccine Technologies Enters Into Agreement With Scancell 64
ImmunoVaccine Enters Into Research Agreement With Yokohama City University 65
ImmunoVaccine Technologies Enters Into Research Agreement With FIT Biotech 66
ImmunoVaccine Technologies Enters Into Agreement With NRC Institute for Biodiagnostics 67
ImmunoVaccine Technologies Enters Into An Agreement With Defence Research and Development Canada 68
ImmunoVaccine Enters Into Collaboration Agreement With National Institutes of Health 69
Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies 70
ImmunoVaccine Technologies Enters Into Co-Development Agreement With DRDC 71
Licensing Agreements 72
Immunovaccine Enters Into License Agreement With Merck 72
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies 74
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies 75
Equity Offering 76
Immunovaccine Completes Private Placement Of Common Stock For $2.8 Million 76
Immunovaccine Completes Public Offering Of $7.22 Million 78
Acquisition 80
ImmunoVaccine Completes Reverse Acquisition Of Rhino Resources 80
ImmunoVaccine Acquires Immunotope 81

Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables


Immunovaccine, Inc., Key Information 7
Immunovaccine, Inc., Key Facts 7
Immunovaccine, Inc. Pipeline by Indication, 2012 9
Immunovaccine, Inc. Pipeline by Stage of Development, 2012 11
Immunovaccine, Inc. Monotherapy Products in Pipeline, 2012 12
Immunovaccine, Inc. Combination Treatment Modalities in Pipeline, 2012 13
Immunovaccine, Inc. Phase I, 2012 14
Immunovaccine, Inc. Pre-Clinical, 2012 15
Immunovaccine, Inc. Discovery, 2012 16
Immunovaccine, Inc. Pipeline By Therapeutic Class, 2012 32
Immunovaccine, Inc. Pipeline By Route of Administration, 2012 33
Immunovaccine, Inc. Pipeline Products By Mechanism of Action, 2012 34
Immunovaccine, Inc. Recent Pipeline Updates, 2012 35
Immunovaccine, Inc. - Discontinued Pipeline Products, 2012 38
Immunovaccine, Inc., Subsidiaries 39
Immunovaccine, Inc., Deals Summary 49
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 51
ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 52
Immunovaccine Technologies Enters Into Research Agreement With OncoTherapy Science 53
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 54
Immunovaccine Enters Into Co-Development Agreement With Oncothyreon 55
Immunovaccine Enters Into Research Agreement With Vaxil BioTherapeutics 56
ImmunoVaccine Enters Into Research Agreement With Dana-Farber 57
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute 62
Immunovaccine Expands Research Agreement With Defence Research And Development Canada 63
ImmunoVaccine Technologies Enters Into Agreement With Scancell 64
ImmunoVaccine Enters Into Research Agreement With Yokohama City University 65
ImmunoVaccine Technologies Enters Into Research Agreement With FIT Biotech 66
ImmunoVaccine Technologies Enters Into Agreement With NRC Institute for Biodiagnostics 67
ImmunoVaccine Technologies Enters Into An Agreement With Defence Research and Development Canada 68
ImmunoVaccine Enters Into Collaboration Agreement With National Institutes of Health 69
Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies 70
ImmunoVaccine Technologies Enters Into Co-Development Agreement With DRDC 71
Immunovaccine Enters Into License Agreement With Merck 72
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies 74
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies 75
Immunovaccine Completes Private Placement Of Common Stock For $2.8 Million 76
Immunovaccine Completes Public Offering Of $7.22 Million 78
ImmunoVaccine Completes Reverse Acquisition Of Rhino Resources 80
ImmunoVaccine Acquires Immunotope 81

List of Figures


Immunovaccine, Inc. Pipeline by Indication, 2012 9
Immunovaccine, Inc. Pipeline by Stage of Development, 2012 11
Immunovaccine, Inc. Monotherapy Products in Pipeline, 2012 12
Immunovaccine, Inc. Combination Treatment Modalities in Pipeline, 2012 13
Immunovaccine, Inc. Pipeline By Therapeutic Class, 2012 32
Immunovaccine, Inc. Pipeline By Route of Administration, 2012 33
Immunovaccine, Inc. - Pipeline Products By Mechanism of Action, 2012 34

Upcoming Reports:

Consumer Electronics Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Technological developments in the consumer electronics industry and product innovations are some of the major factors driving the growth of this market. Emergence of new players owing to increasing growth opportunities in the consumer electronics field is also contributing to the growth of this market. Research and development is been made to develop cost effective consumer electronic goods with innovative designs to withstand the increasing competition. Technologies like 3D and LED TVs are driving the growth as consumers are upgrading their current electronics and seeking the latest...
Still Drinks Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
Description Still drinks refers to drinks that include ready-to-drink fruit or non-fruit that typically contains juice content of lower than 25 percent, and water is also included in this sweetened flavor. Generally, in most countries consumers don’t tend to distinguish between juices, nectars, and the still drinks. It’s mostly the price that determines the consumer buying rather than the juice content. Of all the categories under the soft drinks, the still drinks market has shown continual growth with volumes advancing by almost close to 7% which is highest after...
Smart Airports Market - Global Industry Analysis, Market Size, Share, Growth, Trends, And Forecast, 2012 - 2018
By - Transparency Market Research
Airport operations and business models have evolved dramatically over the last two decades to support the explosive growth of the global airline industry. Regulatory reform and deregulation ushered in a new aviation era in North America, as well as in Europe, Asia, and in emerging countries, producing dramatic traffic growth, diversity, and choice for airline passengers.  Shifting demographics, new corporate governance requirements, and emerging and maturing communication technologies are driving new travel patterns that will require innovative business models and...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...